01/26/23 7:30 AMNasdaq : AGEN conferencesAgenus to Participate in February Investor ConferencesAgenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO, and Dr. Steven O’Day, Chief Medical Officer, willRHEA-AIneutral
01/23/23 7:30 AMNasdaq : AGEN clinical trialAgenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GIOverall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated patients; data suggest superior benefit compared to what has been reported for standard of care and other investigational therapies Responses have been durable with 69% ongoing atRHEA-AIvery positive
01/10/23 8:30 AMNasdaq : AGEN conferencesAgenus to Participate at B Riley Securities’ 2023 Virtual Oncology ConferenceAgenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in aRHEA-AIneutral
12/21/22 8:30 AMNasdaq : AGEN conferencesAgenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GIAgenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company will present expanded data on botensilimab inRHEA-AIneutral
11/17/22 8:30 AMNasdaq : AGEN Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced SarcomaOverall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of therapy Patient responses include sarcoma subtypes that historically do not respond to immunotherapy, including responses in 3 of 4 patients withRHEA-AIpositive
11/16/22 8:30 AMNasdaq : AGEN conferencesAgenus to Participate at 5th Annual Evercore ISI HealthCONx ConferenceAgenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in aRHEA-AIneutral
11/14/22 8:30 AMNasdaq : AGEN Agenus Data at SITC 2022 Highlight Durable Responses of Botensilimab / Balstilimab Combination in Nine Different Treatment-Resistant CancersOverall response rates ranged from 22% in microsatellite stable colorectal cancer (MSS-CRC) to 60% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS-CRC and advanced melanoma; pancreatic cancer to follow before year-endRHEA-AIpositive
11/08/22 8:00 AMNasdaq : AGEN earningsAgenus Provides Corporate Update and Third Quarter 2022 Financial ReportCompany to present expanded data from Phase 1 study of botensilimab (Fc-enhanced anti-CTLA-4) at plenary session of the Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting Initiated Phase 2 ACTIVATE trials of botensilimab in advanced MSS colorectal cancer and advanced melanoma R&D EventRHEA-AIneutral
10/25/22 8:30 AMNasdaq : AGEN earningsAgenus to Provide Corporate Update and Third Quarter 2022 Financial ReportConference Call on Tuesday, November 8, 2022, at 8:30 a.m. ET Company to host “The Road Taken” R&D Event in Boston on November 12 from 2p.m. – 5p.m. ET to discuss with oncology experts clinical experience to date and expected development plans for botensilimab in cold tumors LEXINGTON, Mass., Oct.RHEA-AIneutral
10/13/22 8:32 AMNasdaq : AGEN GSK’s older adult RSV vaccine candidate, containing Agenus’ QS-21 STIMULON™, shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trialData show overall vaccine efficacy of 82.6% against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with consistent high vaccine efficacy observed in severe disease (94.1%), adults aged 70-79 years (93.8%) and those with underlying comorbidities (94.6%) RegulatoryRHEA-AIneutral